Press release
Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, Martinsried chooses Proteros as preferred service partner for kinase drug discovery
Martinsried, Germany, February 21, 2011. Proteros Biostructures GmbH (“Proteros”) and Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced today that Dr. Axel Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery research at the Department of Molecular Biology.Proteros will develop kinase-focused assay systems and provide screening services employing its proprietary platform for screening to support the validation of novel kinase targets for drug discovery.
Dr. Axel Ullrich, co-founder of four drug discovery companies and key researcher in the development of two successfully marketed kinase drugs said that he has chosen Proteros as preferred partner for his continued drug discovery projects. Dr. Ullrich stated that he has successfully cooperated with Proteros on several projects during the past few years and is pleased with Proteros’ performance. Moreover he stated, “Proteros has proven to be a reliable and flexible partner with expertise in characterizing compound-target interactions and in the development of biochemical and cellular assay technologies.”
About Proteros:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis, kinetic and thermodynamic compound-target interaction studies and structure-guided drug discovery with its expertise, industrialized processes and unique technologies for crystallography, screening, and fragment-based lead generation. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in Europe, North America and Japan.
About Dr. Axel Ullrich:
Dr. Ullrich is one of the leading cancer and kinase experts worldwide and among the 10 most cited scientists over the past 30 years. Dr. Ullrich is co-founder of the companies SUGEN, Axxima Pharmaceuticals, U3 Pharma and Kinaxo. His research resulted in the development of anti cancer drugs as Herceptin® and SUTENT®. Dr. Ullrich today is Director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Martinsried.
Contact:
Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 – 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com
Dr. Axel Ullrich
Max-Planck-Institute of Biochemistry
Am Klopferspitz 18a
82152 Martinsried
Germany
Phone: +49 (0) 89 8578 2513
E-Mail: ullrich@biochem.mpg.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, Martinsried chooses Proteros as preferred service partner for kinase drug discovery here
News-ID: 163314 • Views: …
More Releases from Proteros biostructures GmbH
PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities
MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company.
The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception…
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry…
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas.
At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for…
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services.
Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and…
More Releases for Ullrich
Strategies for increasing the value of stock options - analysis by financial exp …
Munich, December 2025 - Stock option programs are a key instrument of modern corporate remuneration. They link the personal performance of managers directly to the economic success of a company. However, such programs often lose their appeal, particularly in phases of stagnating or declining stock markets. Finance and marketing expert Ullrich Angersbach addresses this topic in a detailed analysis and shows which strategic measures can be used to sustainably increase…
Crowdfunding in focus: Financial expert Ullrich Angersbach classifies market and …
Munich, December 2025 - Crowdfunding is seen by many investors as an attractive alternative to traditional capital investments. In a recent analysis, financial expert and business graduate Ullrich Angersbach took a close look at the question of what role crowdfunding investments can actually play in 2025 - and where investors should pay particular attention.
Ullrich Angersbach makes it clear that the crowdfunding market has become highly professionalized in recent years. While…
Extruded Aluminum Tubing Market Riding the Wave: Market Players Exploiting Growt …
"This comprehensive Extruded Aluminum Tubing report offers a deep dive into the global market, encompassing a wide spectrum of analyses to equip you with a profound understanding of its dynamics. Beyond the standard SWOT analysis, our study incorporates a diverse range of analytical approaches, including the insightful PESTLE analysis, qualitative and quantitative assessments, absolute dollar opportunity analysis, and the robust Porter's Five Forces analysis. We leave no stone unturned when…
Global Mobile Ladder Market Reaching New Heights in Safety and Accessibility 203 …
"Mobile Ladder Market" report's each segment and sub-segment is analyzed in detail so that no stone is left unturned in ensuring that the customer receives the top-quality information about the Mobile Ladder Market by Infinity Business Insights. This report will help the viewer in Better Decision Making.
With a CAGR of 8.5% from 2023 to 2030, the global mobile ladder market is anticipated to reach an estimated USD 2.9 billion by…
Extruded Seamless Aluminum Tubing Market to Witness Huge Growth by Key Players: …
ReportsnReports publishes the report titled Extruded Seamless Aluminum Tubing that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital factors…
Amit Gupta passes the baton to Ullrich Loeffler as CEO of Ecosystm
31 March 2022, SINGAPORE: Ecosystm, the disruptive technology research and advisory company today announced the transition of Co-founder and Chief Operating Officer Ullrich Loeffler to the role of Chief Executive Officer. As the group continues its ambitious innovation strategy, Amit Gupta will step into the role of Founder and Chairman.
Ecosystm has seen exponential growth since the company launched in 2018 and has been challenging traditional technology research firms since its…
